Statins do not affect bone anabolism in older women treated with teriparatide.

IF 5.1
Cecilia Oliveri, Anastasia Xourafa, Nunziata Morabito, Agostino Gaudio, Ilaria Politi, Peter Schwartz, Salvatore Minisola, Antonino Catalano
{"title":"Statins do not affect bone anabolism in older women treated with teriparatide.","authors":"Cecilia Oliveri, Anastasia Xourafa, Nunziata Morabito, Agostino Gaudio, Ilaria Politi, Peter Schwartz, Salvatore Minisola, Antonino Catalano","doi":"10.1210/clinem/dgaf523","DOIUrl":null,"url":null,"abstract":"<p><strong>Context: </strong>Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, HMG-CoA reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear.</p><p><strong>Objective: </strong>To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH.</p><p><strong>Methods: </strong>This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25,000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers-alkaline phosphatase (ALP), osteocalcin (OCN), and C-terminal telopeptide of type I collagen (CTX)-were measured every six months.</p><p><strong>Results: </strong>Thirty patients were statin users and seventy-four were non-users. Statin users experienced lumbar spine BMD gain from 0.71±0.16 to 0.79±0.14 g/cm² (p=0.01), and a trend toward femoral neck improvement from 0.53±0.24 to 0.62±0.12 g/cm² (p=0.07). Non-users also showed lumbar spine BMD rise from 0.70±0.10 to 0.77±0.11 g/cm² (p=0.001), with no significant femoral neck BMD change from 0.60±0.11 to 0.58±0.15 g/cm² (p=0.5). At the end of the observation period, CTX levels were significantly lower in statin users compared to non-users (0.37±0.29 vs 0.66±0.47 ng/mL, p=0.007). Conversely, no significant intergroup differences were observed for ALP and OCN throughout the observation period.</p><p><strong>Conclusion: </strong>Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, and it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-09-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf523","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

Context: Teriparatide [rhPTH (1-34)] is an established anabolic agent for the treatment of severe osteoporosis. Statins, HMG-CoA reductase inhibitors, have demonstrated antiresorptive properties, but their impact on the anabolic efficacy of rhPTH remains unclear.

Objective: To evaluate whether concurrent statin therapy influences changes in bone mineral density (BMD) and bone turnover markers in women receiving rhPTH.

Methods: This retrospective cohort study included 104 postmenopausal women with severe osteoporosis who completed 24 months of daily rhPTH (20 mcg subcutaneously) and biweekly cholecalciferol (25,000 IU). Patients were stratified by statin use. BMD at the lumbar spine and femoral neck was assessed at baseline and study completion. Bone turnover markers-alkaline phosphatase (ALP), osteocalcin (OCN), and C-terminal telopeptide of type I collagen (CTX)-were measured every six months.

Results: Thirty patients were statin users and seventy-four were non-users. Statin users experienced lumbar spine BMD gain from 0.71±0.16 to 0.79±0.14 g/cm² (p=0.01), and a trend toward femoral neck improvement from 0.53±0.24 to 0.62±0.12 g/cm² (p=0.07). Non-users also showed lumbar spine BMD rise from 0.70±0.10 to 0.77±0.11 g/cm² (p=0.001), with no significant femoral neck BMD change from 0.60±0.11 to 0.58±0.15 g/cm² (p=0.5). At the end of the observation period, CTX levels were significantly lower in statin users compared to non-users (0.37±0.29 vs 0.66±0.47 ng/mL, p=0.007). Conversely, no significant intergroup differences were observed for ALP and OCN throughout the observation period.

Conclusion: Statin use does not impair the anabolic efficacy of rhPTH in increasing BMD in postmenopausal women with severe osteoporosis, and it provides additional antiresorptive benefits during rhPTH therapy. These findings support the continued use of statins and highlight the need for further prospective studies exploring synergistic effects.

他汀类药物对接受特立帕肽治疗的老年妇女的骨合成代谢没有影响。
背景:特立帕肽[rhPTH(1-34)]是治疗严重骨质疏松症的合成代谢药物。他汀类药物,HMG-CoA还原酶抑制剂,已经显示出抗吸收特性,但它们对甲状腺赘激素合成代谢功效的影响尚不清楚。目的:评价并发他汀类药物治疗是否影响rhPTH患者骨密度(BMD)和骨转化指标的变化。方法:这项回顾性队列研究纳入了104名患有严重骨质疏松症的绝经后妇女,她们完成了24个月的每日rhPTH (20 mcg皮下注射)和两周的胆钙化醇(25,000 IU)。患者按他汀类药物的使用进行分层。在基线和研究完成时评估腰椎和股骨颈的骨密度。骨转换标志物-碱性磷酸酶(ALP)、骨钙素(OCN)和I型胶原c端末端肽(CTX)-每六个月测量一次。结果:他汀类药物使用者30例,非他汀类药物使用者74例。他汀类药物使用者腰椎骨密度从0.71±0.16增加到0.79±0.14 g/cm²(p=0.01),股骨颈骨密度从0.53±0.24增加到0.62±0.12 g/cm²(p=0.07)。非使用者的腰椎骨密度也从0.70±0.10上升到0.77±0.11 g/cm²(p=0.001),股骨颈骨密度从0.60±0.11上升到0.58±0.15 g/cm²(p=0.5)。在观察期结束时,他汀类药物使用者的CTX水平明显低于非他汀类药物使用者(0.37±0.29 vs 0.66±0.47 ng/mL, p=0.007)。相反,在整个观察期内,ALP和OCN在组间无显著差异。结论:他汀类药物的使用并不影响促性腺激素增加绝经后严重骨质疏松症妇女骨密度的合成代谢作用,并且在促性腺激素治疗期间提供额外的抗骨吸收益处。这些发现支持继续使用他汀类药物,并强调需要进一步的前瞻性研究来探索协同效应。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信